306 OPTIMIZING ADHERENCE TO QUADRUPLE THERAPY FOR H PYLORI ERADICATION AMONGST ETHNIC MINORITIES: A QUALITY IMPROVEMENT INITIATIVE AT A SAFETY-NET MEDICAL CENTER Read More →
1262 MOLECULAR IRREVERSIBLENESS IS REMAINED IN ADJACENT MUCOSA OF GASTRIC CANCER MORE THAN 10 YEARS AFTER HELICOBACTER PYLORI ERADICATION Read More →
1259 DDIT4 PREVENTS HELICOBACTER PYLORI-INDUCED GASTRIC METAPLASIA THROUGH METABOLIC REGULATION OF FERROPTOSIS Read More →
1258 THE ROLE OF WEE1 IN GASTRIC CANCER PROGRESSION AND IMMUNE EVASION: INSIGHTS FROM H. PYLORI INFECTION Read More →
656 A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY PHASE III CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF BISMUTH QUADRUPLE THERAPY CONTAINING TEGOPRAZAN COMPARED TO ESOMEPRAZOLE IN ERADICATING HELICOBACTER PYLORI IN CHINA Read More →
Sa1352 ARGENTINEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT: EFFECTIVENESS OF FIRST AND SECOND-LINE EMPIRICAL TREATMENT Read More →
Sa1358 RISK OF SEVERE PEPTIC ULCER DISEASE ASSOCIATED WITH HELICOBACTER PYLORI INFECTION IN A LARGE, COMMUNITY-BASED U.S. POPULATION Read More →
Sa1356 RISK OF MAP-LIKE REDNESS DEVELOPMENT, MAJOR RISK FACTOR OF GASTRIC CANCER, AFTER ERADICATION THERAPY FOR HELICOBACTER PYLORI INFECTION Read More →
Sa1355 REDUCTION IN HELICOBACTER PYLORI INFECTION AMONG PATIENTS REFERRED FOR UPPER GASTROINTESTINAL ENDOSCOPY IN SANTIAGO, CHILE, BETWEEN 2010-2020 Read More →
Sa1354 HELICOBACTER PYLORI TREATMENT REDUCES THE RISK OF GASTRIC CANCER FOR HIGH GENETIC RISK POPULATIONS: A LONGITUDINAL STUDY Read More →
Sa1353 INFLUENCE OF H. PYLORI TREATMENT ON METACHRONOUS RECURRENCE IN ELDERLY PATIENTS AFTER ENDOSCOPIC RESECTION OF GASTRIC CANCER: A NATIONWIDE COHORT STUDY Read More →
Sa1360 HELICOBACTER PYLORI DIAGNOSTIC TESTS AND INDICATIONS OF TREATMENT FROM THE LATIN AMERICAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-LATAMREG). Read More →
Sa1351 INSIGHTS INTO THE EPIDEMIOLOGY AND DETERMINANTS OF HELICOBACTER PYLORI-NEGATIVE GASTRITIS: A COMPREHENSIVE ANALYSIS Read More →
